Cross-trial prediction of treatment response to transcranial direct current

stimulation in patients with major depressive disorder 2

- Gerrit Burkhardt, MD^{1,2}; Stephan Goerigk, PhD^{1,2,3}; Lucia Bulubas, MD, PhD^{1,2}; Esther Dechantsreiter, 3
- M.Sc. 1,2; Daniel Keeser, PhD1,2; Ulrike Vogelmann, MD2,4; Katharina von Wartensleben1; Johannes 4
- Wolf, MD^{1,2}; Christian Plewnia, MD^{5,6}; Andreas Fallgatter, MD^{5,6}; Berthold Langguth, MD⁷; Claus 5
- Normann, MD^{8,9}; Lukas Frase, MD^{8,10}; Peter Zwanzger, MD^{1,11}; Thomas Kammer, MD^{12,13}; Carlos 6
- Schönfeldt-Lecuona, MD^{12,13}; Daniel Kamp, MD¹⁴; Malek Bajbouj, MD^{15,16}; Nikolaos Koutsouleris, 7
- MD^{1,2}; Andre R Brunoni, MD, PhD ^{17,*}; Frank Padberg, MD^{1,2,*} 8
- 10 ¹Department of Psychiatry and Psychotherapy, LMU University Hospital, Munich, Germany
- ²German Center for Mental Health (DZPG), Site Munich-Augsburg, Germany 11
- 12 ³Charlotte Fresenius Hochschule, University of Psychology, Munich, Germany
- 13 ⁴Department of Psychiatry and Psychotherapy, University Hospital, Technical University of Munich
- 14 (TUM), Munich, Germany
- ⁵Tübingen Center for Mental Health, Department of Psychiatry and Psychotherapy, University of 15
- 16 Tübingen, Tübingen, Germany
- ⁶German Center for Mental Health (DZPG), Site Tübingen, Germany 17
- 18 ⁷Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany
- 19 ⁸Department of Psychiatry and Psychotherapy, Medical Center, University of Freiburg, Freiburg,
- 20 Germany

1

9

- 21 ⁹Center for Basics in Neuromodulation (NeuroModulBasics), University of Freiburg, Freiburg,
- 22 Germany

34

43

- 23 ¹⁰Department of Psychosomatic Medicine and Psychotherapy, Medical Center, University of Freiburg
- 24 ¹¹kbo-Inn-Salzach-Klinikum, Clinical Center for Psychiatry, Psychotherapy, Psychosomatic Medicine,
- 25 Geriatrics and Neurology, Gabersee, Wasserburg/Inn, Germany
- 26 ¹²Department of Psychiatry and Psychotherapy III, University of Ulm, Ulm, Germany
- 27 ¹³German Center for Mental Health (DZPG), Site Mannheim-Heidelberg-Ulm, Germany
- 28 ¹⁴Department of Psychiatry and Psychotherapy, LVR-Klinikum Düsseldorf, Heinrich-Heine-
- 29 Universität Düsseldorf, Medical Faculty, Düsseldorf, Germany
- 30 ¹⁵Department of Psychiatry and Psychotherapy, Charité-Campus Benjamin Franklin, Berlin, Germany
- 31 ¹⁶German Center for Mental Health (DZPG), Site Berlin-Potsdam, Germany
- 32 ¹⁷Department of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil
- 33 * These authors equally contributed to the manuscript
- 35 Corresponding author:
- 36 Dr. Gerrit Burkhardt
- Department of Psychiatry and Psychotherapy 37
- 38 LMU University Hospital
- 39 Nußbaumstraße 7
- 40 80336 Munich, Germany
- E-Mail: gerrit.burkhardt@med.uni-muenchen.de 41
- 42 Telephone: +1149 89 4400 53381
- 44 Running title: Cross-trial prediction of tDCS response in MDD

It is made available under a CC-DT 4.0 international license

Abstract

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

666768697071

Machine-learning (ML) classification may offer a promising approach for treatment response prediction in patients with major depressive disorder (MDD) undergoing non-invasive brain stimulation. This analysis aims to develop and validate such classification models based on easily attainable sociodemographic and clinical information across two randomized controlled trials on transcranial direct-current stimulation (tDCS) in MDD. Using data from 246 patients with MDD from the randomized-controlled DepressionDC and ELECT-TDCS trials, we employed an ensemble machine learning strategy to predict treatment response to either active tDCS or sham tDCS/placebo, defined as $\geq 50\%$ reduction in the Montgomery-Åsberg Depression Rating Scale at 6 weeks. Separate models for active tDCS and sham/placebo were developed in each trial and evaluated for external validity across trials and for treatment specificity across modalities. Additionally, models with abovechance detection rates were associated with long-term outcomes to assess their clinical validity. In the DepressionDC trial, models achieved a balanced accuracy of 63.5% for active tDCS and 62.5% for sham tDCS in predicting treatment responders. The tDCS model significantly predicted MADRS scores at the 18-week follow-up visit ($F_{(1.60)} = 4.53$, $p_{FDR} = .037$, $R^2 = 0.069$). Baseline self-rated depression was consistently ranked as the most informative feature. However, response prediction in the ELECT-TDCS trial and across trials was not successful. Our findings indicate that ML-based models have the potential to identify responders to active and sham tDCS treatments in patients with MDD. However, to establish their clinical utility, they require further refinement and external validation in larger samples and with more features.

Introduction

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

Major Depressive Disorder (MDD) represents a significant global health challenge, ranking as one of the main causes of disability worldwide¹. Despite the availability of effective treatments ranging from pharmacotherapy and psychotherapy to non-invasive and invasive neurostimulation, many patients do not achieve remission, even after multiple therapeutic attempts². The development of new interventions has proven challenging, possibly due to the heterogeneity of MDD symptoms³, its varying time course⁴, and a lack of robust biological correlates^{5,6}. While multiple sociodemographic, clinical, genetic, and neuroimaging variables have been associated with responses to common treatments like antidepressant medication, these associations have not yet resulted in stratified patient selection algorithms or targeted interventions. Thus, recent research has focused on developing multivariate predictive models that might enable pre-treatment stratification at the individual patient level^{8,9} and detect effects beyond the between-group level in randomized controlled trials (RCT)^{9,10}. Within this approach, initial machine learning (ML)-based predictive models are typically trained on data from existing RCTs to identify responders to the treatments under investigation^{8,11,12}. Models then require testing in independent samples and across diverse populations to ensure their generalizability to unseen patients before they are finally tested prospectively for clinical utility. However, efforts to externally validate initial models remain sparse¹³, and consequently, few attempts have been made to validate treatment prediction models in RCTs¹⁴. Predictive approaches are particularly relevant in the field of non-invasive brain stimulation (NIBS), including repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS), as the clinical application of these interventions is rapidly growing. tDCS is a safe, well-tolerated, and easily applicable treatment option for patients with MDD¹⁵⁻¹⁷, but has yielded inconclusive results in recent confirmatory multicenter RCTs^{18–20}. Therefore, efforts to optimize outcomes on the individual patient level are required to develop the intervention toward clinical applicability^{21,22}. A recent study reported a high predictive accuracy of an ML-based prediction model for identifying responders to bifrontal transcranial direct current stimulation (tDCS), yet lacked external validation²³. For rTMS, ML studies have mainly focused on other neuropsychiatric

conditions, e.g. schizophrenia^{9,10}. To our knowledge, there are currently no studies available utilizing ML models across RCTs on NIBS interventions.

To investigate whether sociodemographic and clinical data are informative for predicting the individual response to tDCS, we used data from two large RCTs on basically identical tDCS protocols (i.e. bifrontal electrode montage: anode left and cathode right dorsolateral prefrontal cortex [DLPFC], 2 mA intensity and 30 min duration), that were performed in Brazil¹⁶ and Germany¹⁸, evaluating the efficacy of tDCS in patients with MDD. We aimed to develop and externally validate ML-based prediction models to identify patients likely to benefit from tDCS, test those models for treatment specificity, and explore their clinical validity and utility based on long-term outcomes.

Subjects and Methods

Study design

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

In this secondary analysis of two randomized, blinded, sham-controlled trials, we used an ensemble ML-based strategy with nested cross-validation to identify patients with response to either active tDCS or sham/placebo treatment using sociodemographic and clinical baseline variables. Models were trained separately in each trial for each treatment modality and then applied 1.) across trials to test for external validity and 2.) across treatment modalities to test if predictions were specific to the treatment (see Figure 1). Classification probabilities of models with above-chance detection rates were then associated with long-term outcomes at follow-up to explore the clinical validity and utility of the predictions.




Figure 1. Model development and validation

Study population

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

We analyzed patients with MDD from two trials: 1.) DepressionDC (trial registration: NCT02530164) was a multicenter RCT investigating the efficacy of 6 weeks of bifrontal tDCS as an additional treatment to selective serotonin reuptake inhibitors (SSRI) in patients with MDD¹⁸. Between January 2016 and June 2020, 160 patients were recruited at seven university hospitals and one psychiatric community hospital in Germany. Active tDCS was not superior to sham tDCS in reducing depressive symptoms. 2.) The Escitalopram versus Electrical Current Therapy for Treating Depression Clinical Study (ELECT-TDCS; trial registration: NCT01894815) was a single-center, non-inferiority RCT comparing active tDCS plus placebo medication, escitalopram plus sham tDCS, and sham tDCS plus placebo medication in patients with MDD over 10 weeks¹⁶. Two hundred forty-five patients were recruited at the University of São Paulo, Brazil, between October 2013 through July 2016. Active tDCS was not non-inferior to escitalopram but superior to placebo treatment.

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

Both trials employed rigorous RCT methods with stringent randomization, blinding protocols, and non-active sham conditions. Participants were selected based on the DSM-5 criteria for MDD while excluding patients with bipolar disorder, substance abuse or dependence, dementia, and personality disorders. However, DepressionDC enrolled patients currently receiving SSRIs, whereas ELECT-TDCS required participants to be antidepressant-free. Furthermore, DepressionDC permitted the inclusion of patients with marginally lower symptom severity, as assessed by the Hamilton Depression Rating Scale (HDRS), and restricted participation to a narrower age range. A comprehensive list of eligibility criteria for both trials is provided in the supplement. The intervention followed a basically identical tDCS protocol with 2 mA stimulation of the DLPFC over 30 minutes per session. However, protocols differed in precise electrode placement, i.e. DepressionDC using the F3 (anode) and F4 (cathode) based on the international electroencephalogram 10-20 system, and ELECT-TDCS the Omni-Lateral-Electrode (OLE) system (left DLPFC anode and right DLPFC cathode) with slightly more lateral positions of electrodes²⁴. Also, treatment lasted 10 weeks with a total of 22 treatment sessions (15 sessions in the first 3 weeks and 7 weekly sessions for the remaining treatment period) in ELECT-TDCS versus 6 weeks with a total of 24 treatment sessions (20 sessions in the first 4 weeks and 2 sessions per week for 2 weeks) in DepressionDC, with efficacy assessed at these time points using the HDRS and Montgomery-Åsberg Depression Rating Scale (MADRS) as primary outcome measures, respectively. Weekly MADRS scores were additionally collected in ELECT-TDCS as a secondary outcome measure. We used data from all patients with available depression scores on the MADRS at baseline and week 6 after randomization. Thus, the analysis included 136 (active tDCS: 72 patients; sham tDCS: 64 patients) out of 150 patients from the DepressionDC sample and 110 (active tDCS + placebo: 66 patients; sham tDCS + placebo: 44 patients) out of 154 patients from the respective treatment arms of the ELECT-TDCS sample. All participants had provided their written informed consent before inclusion in the respective study. Both studies were approved by the local ethics committees and conducted in accordance with the Declaration of Helsinki.

Prediction target and features

Participants were classified as treatment responders if they achieved a $\geq 50\%$ reduction from baseline to week 6 on the 10-item MADRS (score range 0-60; higher scores indicate more severe depression)²⁵. Pursuing a data-driven approach, we included all variables available across the studies at baseline as potential predictors. This amounted to 15 features, including basic sociodemographic information (age, sex, years of education, marriage, unemployment), medical history (body mass index, smoker status, diagnoses of hypertension, diabetes, and/or hypothyroidism), psychiatric history

(age of MDD onset, duration of MDD episode, family history of MDD), and baseline depression

severity (MADRS and Beck Depression Inventory-II [BDI-II] total scores).

Machine learning analysis

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

All ML analyses were conducted using the in-house, open-source software package NeuroMiner, version 1.05 (https://github.com/neurominer-git/NeuroMiner-1), running on MATLAB (version R2022a). We used repeated nested cross-validation (CV) with 10 folds and 5 repetitions at both the inner (CV_1) and outer (CV_2) loops to strictly separate the training and testing of the models. In each CV₁ fold, we scaled all features from 0 to 1 and substituted missing values via 7-nearest neighbor-based imputation (Euclidean distance for continuous, Hamming distance for categorical variables)²⁶. Following a previous approach^{27,28}, each processed CV₁ training sample then entered a greedy stepwise forward search wrapper employing a linear support vector machine algorithm (SVM; LIBSVM 3.12²⁹) to iteratively select a subset of 50% features with highest predictive performance (balanced accuracy $[\textit{BAC} = \frac{\textit{sensitivity} + \textit{specificity}}{2}]^{30}$ on the held-out CV_1 data) across a range of Chyperparameters $(2^{[-4} \in \mathbb{Z} \to +4])$. To account for uneven distributions of the outcome labels (response/non-response), optimal C hyperparameters were multiplied with the inverse ratio of the training group sizes³¹. For each CV₁ permutation, all CV₁ models were retrained with the optimal model hyperparameters, and this ensemble was then applied to the CV₂ test data without modification. Classification probabilities for each CV₂ test subject were retrieved by combining the decisions across all models. We calculated permutation-based p-values to define which models reached above-chance

detection rates (α =0.05; 1000 permutations)³². To understand which features were most reliably contributing to the prediction of treatment response, we computed the CV ratio³³. The feature importance of variables was further estimated using sign-based consistency mapping³⁴. For cross-trial and cross-treatment modality validation, we applied CV₁ ensembles with permutation-based abovechance detection rates without modification to the respective other samples. Out-of-sample performance metrics were calculated by comparing the predicted versus the observed outcome labels over all CV₂ predictions.

Post-hoc clinical validation

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

Additional validation analyses and visualizations were performed in R, version 4.3.2³⁵. Results were considered significant at α =0.05. To explore the clinical validity of all classifiers with above-chance detection rates, we fit linear mixed models (LMM) using the lme4 package³⁶ to predict MADRS and GAF changes from baseline until the trials' follow-up appointments based on the models' assigned probability to be a responder (formula: change ~ assigned probability). The model included the treatment site as a random effect (formula: ~1| site). The significance of the model factors was determined using omnibus tests (type III ANOVA) with Satterthwaite approximation to degrees of freedom.

Results

Main classifiers

In the DepressionDC trial, 24 patients (33%) had responded to active tDCS treatment at week 6. Compared to tDCS non-responders, these patients were significantly older (mean [SD] age: 37 [13] vs. 30 [13]; p=0.023) and showed lower clinician-rated (mean [SD] MADRS scores: 22 [5] vs. 26 [6]; p=0.049) and self-reported depression severity (mean [SD] BDI scores: 23 [9] vs. 30 [11]; p=0.011) at baseline (other baseline characteristics are shown in Table 1). The classifier ensemble predicted tDCS responders with an above-chance cross-validated BAC of 63.5% (P=0.001; Table 2; Figure 2), increasing the prognostic certainty compared to the base rate (prognostic summary index of 24.1%).

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

In the sham group, 32 patients (50%) showed a treatment response. Compared to sham nonresponders, these patients had lower clinician-rated (mean [SD] MADRS scores: 22 [5.3] vs. 24.3 [4.4]; p=0.017) and self-reported depression severity (mean [SD] BDI scores: 23 [9] vs. 30 [10]; p=0.005) at baseline. Sham responders were predicted with an above-chance cross-validated BAC of 62.5% (p=0.023; Table 2) and prognostic summary index of 25.1%. In both the tDCS and sham analyses, only baseline BDI scores reliably and significantly contributed to the classifier decisions (Figure 3). In the ELECT trial, 27 patients (41%) had responded to active tDCS treatment at week 6. Compared to tDCS non-responders, they had higher clinician-rated depression at baseline (mean [SD] MADRS scores: 29 [8] vs. 26 [6]; p=0.020). Responders were predicted with a BAC of 61.0% that did not reach our above-chance detection criterion (p=0.071; Table 2). Similarly, our analysis did not yield models with above-chance detection rates for the 14 (32%) responders to sham treatment (BAC=42.9%; p=0.88; Table 2). External validation and treatment specificity Models with above-chance detection rates did not generalize across trials. The DepressionDC tDCS classifier showed a BAC of 51.1% in the ELECT tDCS sample, and the DepressionDC sham classifier reached a BAC of 55.5% in the ELECT sham sample (shown in Table 2). Models also did not reach above-chance detection rates across treatment modalities, with the DepressionDC tDCS model showing a BAC of 53.1% when applied to the DepressionDC sham arm and the DepressionDC sham model showing a BAC of 53.1% when applied to the DepressionDC tDCS arm.

Table 1. Baseline characteristics of patients with MADRS response and non-response to tDCS

Feature	Dep	pressionDC		ELECT				
	Non-responder, n = 48 ^a	Responder, $n = 24^a$	p- value ^b	Non-responders, n = 39 ^a	Responder, n = 27 ^a	p- value ^b		
Sex			0.9			0.3		
Female	29 (60%)	14 (58%)		25 (66%)	21 (78%)			
Male	19 (40%)	10 (42%)		13 (34%)	6 (22%)			
Age at randomization - years	37 (13)	43 (14)	0.1	44 (13)	47 (11)	0.2		
Age of depression onset - years	30 (13)	37 (13)	0.023	27 (12)	28 (12)	0.8		
Duration of episode - weeks	56 (67)	52 (56)	>0.9	28 (72)	26 (33)	0.7		
Family history of depression	21 (46%)	15 (65%)	0.1	26 (67%)	19 (70%)	0.8		
Years of education	11.91 (2.28)	11.50 (1.65)	0.5	15.8 (4.5)	14.0 (4.7)	0.2		
Unemployed	3 (9.1%)	0 (0%)	0.5	13 (35%)	10 (37%)	0.9		
Married	5 (15%)	6 (43%)	0.1	19 (49%)	16 (59%)	0.4		
Body mass index - kg/m ²	25.7 (5.2)	27.9 (5.9)	0.1	25.8 (4.7)	25.7 (4.6)	>0.9		
Smoker	21 (44%)	7 (29%)	0.2	7 (18%)	5 (19%)	>0.9		
Hypertension	4 (10%)	4 (24%)	0.2	9 (24%)	5 (19%)	0.7		
Diabetes	1 (2.5%)	0 (0%)	>0.9	3 (7.9%)	1 (3.7%)	0.6		
Hypothyroidism	2 (5.0%)	4 (24%)	0.1	8 (21%)	5 (19%)	0.8		
MADRS score at baseline	26 (6)	22 (5)	0.049	26 (6)	29 (8)	0.020		
BDI score at baseline	30 (11)	23 (9)	0.011	30 (10)	30 (11)	0.7		

^aMean (SD); n (%). ^b Pearson's Chi-squared test; Wilcoxon rank sum test. Fisher's exact test.

245

Table 2. Prediction results of MADRS response models.

249 250

Model	TP	TN	FP	FN	Sens	Spec	PPV	NPV	PSI	AUC	BAC	p-value
DDC tDCS	17	27	21	7	70.8	56.2	44.7	79.4	24.1	0.64	63.5	0.001
applied to ELECT tDCS	11	24	15	16	40.7	61.5	42.3	60.0	2.3	0.50	51.1	-
applied to DDC sham	17	17	15	15	53.1	53.1	53.1	53.1	6.2	0.62	53.1	-
DDC sham	20	20	12	12	62.5	62.5	62.5	62.5	25.0	0.67	62.5	0.023
applied to ELECT sham	9	14	16	5	64.3	46.7	36.0	73.7	9.7	0.59	55.5	-
applied to DDC tDCS	14	23	25	10	58.3	47.9	35.9	69.7	5.6	0.54	53.1	-
ELECT tDCS	17	23	16	10	63.0	59.0	51.5	69.7	21.2	0.60	61.0	0.07
ELECT sham	5	15	15	9	35.7	50.0	25.0	62.5	-12.5	0.44	42.9	0.88

Abbreviations: TP, True Positive; TN, True Negative; FP, False Positive; FN, False Negative; Sens, Sensitivity; Spec, Specificity; PPV, Positive Predictive Value; NPV, Negative Predictive Value; PSI, Prognostic Summary Index; AUC, Area Under the Curve; BAC, Balanced Accuracy. Note: p-values were calculated using permutation analysis (α=0.05; 1000 permutations).




Figure 2. Permutation-based significance. Response was defined as $\geq 50\%$ reduction from baseline.




Figure 3. Feature importance. A positive cross-validation ratio suggests that a higher feature value predicts MADRS response, whereas a negative ratio implies that lower values do. A higher sign-based consistency suggests that feature weights were more consistently positive or negative across the ensemble. Significance was assessed by defining a hypothesis test for the importance score with a null hypothesis of 0 and an alternative hypothesis of not 0. FDR-corrected p-values were then calculated using a cumulative distribution function of zscores (α =0.05; red dotted line).

Post-hoc clinical validation

251

252 253

254

256

257

258

259

260

261

262 263

264

265

266

267

268

269

For the DepressionDC tDCS model, classification probabilities significantly predicted MADRS scores at the 18-week follow-up visit ($F_{(1.60)} = 4.53$, $p_{FDR} = .037$, $R^2 = 0.069$), but not MADRS scores at week 30 or GAF scores at weeks 18 and 30 (Supplementary Table S2 and Supplementary Figure S1). Classification probabilities of the DepressionDC sham model did not predict MADRS or GAF outcomes at weeks 18 and 30.

Discussion

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

To our knowledge, this is the first study testing the cross-trial validity of ML models trained on easily attainable sociodemographic and clinical baseline variables to predict responders to a NIBS intervention. Whereas ML models increased accuracy in identifying responders to active tDCS and sham tDCS in the 6-week multicenter, randomized-controlled DepressionDC trial, the same variable battery could not be utilized to predict responses in the ELECT-TDCS trial, and models did not generalize across trial datasets and treatment modalities. Our findings underscore existing challenges and limitations inherent in predicting antidepressant responses in RCT populations.

The predictive accuracies of our models with above-chance detection rates align with prior attempts to predict responses to antidepressant medication using ML algorithms trained on clinical variables^{9,11,12,37}. Although these performances are modest compared to the classification benchmarks set in other medical disciplines, such as neuroradiology³⁸, antidepressant response prediction remains a challenging task relying on subjective judgment, and thus, even small increases in predictive accuracy might theoretically inform clinical decisions. However, as exemplified by the only prior attempt to prospectively assess the clinical utility of an antidepressant response classifier, which failed to improve treatment outcomes when applied as a decision-making tool¹⁴, strong indicators are needed to justify further development of classifiers beyond the proof-of-concept stage. In the context of our study, the tDCS response classifier for the DepressionDC sample significantly predicted depression severity at the 18-week follow-up visit, suggesting potential clinical validity. Nonetheless, given the failed external validation and the need for enhanced performance, further refinement and testing of the model would be needed to establish its efficacy and reliability³⁹.

Recent research, including a validation attempt across trials on antipsychotic medication for schizophrenia⁴⁰, suggests that three main reasons might have contributed to our models' failed transferability across trial datasets. First, trial populations might have been too heterogeneous, including patients at different disorder stages or with nuanced differences in psychopathology profiles not captured by the broad DSM-5 inclusion criteria. Indeed, participants in the DepressionDC trial showed numerically later depression onset and longer mean depression episode duration compared to

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

ELECT-TDCS^{16,18}. By contrast, baseline depression severity was comparable between trials. Second, compared to a previous ML prediction study in the ELECT-TDCS cohort²³, our models showed considerably lower predictive performance in the same dataset. Since our analysis aimed to develop generalizable prediction models across two RCT cohorts, we took several methodological choices that may partly explain this difference. Instead of an XGBoost classifier, we used a validated ensemble learning strategy applying SVM algorithms within a nested cross-validation framework. This framework was chosen because it has been applied in several multisite analyses and optimized to generate generalizable models^{9,27,28}. We also limited the input variables to features available in both datasets. Consequently, this meant omitting data modalities like neuropsychological test results, electrophysiological data, and imaging measurements, which might have been needed to specifically detect patterns of response in the active treatment arm. For example, a recent analysis on data from the RESIS trial, which like the DepressionDC trial was also negative regarding its primary and secondary outcomes, extended a previous attempt to built an active rTMS treatment response classifier for patients with predominant negative-symptom schizophrenia based on structural Magnetic Resonance Imaging (sMRI)⁹ by incorporating further data domains (i.e. polygenic risk scores) and multimodal sequential modelling¹⁰. While not yet validated, this approach improved the prediction performance from 80 % to 94% in the active treatment but not the sham treatment arm. Third, treatment response rates could have been overly influenced by contextual factors that cannot be modeled at the single-subject level. For example, the present trials were conducted in healthcare settings with differing models of reimbursement and access to care. They also subtly differed in eligibility criteria, with participants in the DepressionDC trial kept on a stable SSRI dose while participants in ELECT-TDCS were antidepressant-free. These methodological challenges showcase the current need in ML-based treatment prediction research to systematically assess and compare potential analytic pipelines in larger samples, to include comprehensive phenotyping in RCT protocols, and to harmonize best-practice symptom assessments across brain stimulation trials. Models with above-chance detection rates for active tDCS and sham tDCS in the DepressionDC sample also did not generalize across treatment modalities. Our feature importance analyses indicated that the performance of both models was predominantly driven by baseline BDI

scores. This reliance on a single feature presents an interpretative challenge: Without a distinct feature selection profile, it becomes difficult to determine whether the models are tailored specifically to each treatment modality or if they lack generalizability to new patients.

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

Our analysis has several limitations. Firstly, the relatively small sample size in both datasets might have limited the performance and robustness of our classifiers⁴¹. Secondly, only a limited set of identical features was available from both trials. For example, negative affect, which was a key predictive feature in the prior ML analysis of the ELECT-TDCS sample²³, was not collected in DepressionDC. This omission might have reduced the predictive accuracy of models in the present analysis. Thirdly, our study was retrospective and served as a proof-of-concept analysis. Consequently, our models have not been validated prospectively, nor have they been benchmarked against clinical judgments. Fourthly, the DepressionDC trial did not demonstrate the efficacy of active tDCS at a group level. This raises the possibility that there may not have been any discernible effects at the individual subject level either, which would inherently limit the potential of our models to identify specific treatment effects. Lastly, while Kambeitz et al. 23 evaluated treatment response at week 10, we opted to identify responders at week 6 due to the availability of MADRS data at this time point across both trials. Consequently, our study could not explore and compare predictive accuracies at various endpoints.

In conclusion, our findings suggest that readily accessible clinical variables at baseline, particularly self-rated depression severity, have the potential to identify responders to active tDCS and sham tDCS treatments in patients with MDD. However, our findings also caution against the premature dissemination of predictive models that lack external validation. Future research should aim to harmonize and deepen phenotyping efforts in RCT protocols to enable the development of more robust predictive models. Ultimately, such models need to be first externally validated and then prospectively tested for their clinical utility.

Acknowledgements

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

This research was funded by grant 01EE1403E within the German Center for Brain Stimulation research consortium by the German Federal Ministry of Education and Research and supported within the initial phase of the German Center for Mental Health (Deutsches Zentrum für Psychische Gesundheit [DZPG], grant 01EE2303A). GB was supported by two internal grants for young researchers from the Medical Faculty of LMU Munich (FöFoLe, grant number 1127; FöFoLe+, grant number CS063). JW was supported by an internal grant for young researchers from the Medical Faculty of LMU Munich (FöFoLe, grant number 1150).

Conflict of Interest

GB, SG, LB, ED, DK, UV, KW, JW, AF, CN, PZ, TK, CS, NK and AB have no competing interests to declare. CP has received grants from the German Federal Ministry of Education and Research (01KG2003, 01EE1407H, and 01EE1403D) and the Deutsche Forschungsgemeinschaft (PL 525/4-1, PL 525/6-1, and PL 525/6-1) and holds stock options for PsvKit (Tübingen, Germany), BL has received grants from Bayhost, the EU (European School for Interdisciplinary Tinnitus Research [722046] and the Unification of Treatments and Interventions for Tinnitus Patients [848261]), and Neuromod; consulting fees from Neuromod, Decibel Therapeutics, Schwabe, Rovi, Sound Therapeutics, Sonovam, and Sea Pharma; payments from Schwabe, Neuromod, and Desyncra for lectures; payments from Schwabe for expert testimony; has a pending patent for neuronavigated transcranial magnetic stimulation coil positioning for the treatment of tinnitus; participated on a data safety monitoring board or advisory board for the Technical University of Munich (Nicstim) and Neuromod (TENT A2, TENT A3); has a chair on the executive committee of the German Society for Brain Stimulation in Psychiatry and has a fiduciary role in the Tinnitus Research Initiative; has stock or stock options from Sea Pharma; and has received free rental equipment from Magventure, Deymed, and Necstim. LF has received author royalties for book chapters from Wiley-Blackwell, Georg Thieme Verlag, Urban & Fischer Verlag, and Elsevier; and payments for classes from the German Sleep Society, the European Sleep Research Society, and Medical Association Freiburg. DK has

received a grant from the Manfred-Strohscheer Foundation for the Activity of Cerebral Networks, Amyloid and Microglia in Alzheimer's Disease (ActiGliA) project and has received travel and hotel expenses for an invited talk from the EU-funded Stimulation in Pediatrics project.MB has received consulting fees from Parexel and Bayer and payments for lectures from Johnson & Johnson. LF has received author royalties for book chapters from Wiley-Blackwell, Georg Thieme Verlag, Urban & Fischer Verlag, and Elsevier; and payments for classes from the German Sleep Society, the European Sleep Research Society, and Medical Association Freiburg. FP has received grants from the German Research Foundation (BR 4264/6-1) and the German Federal Ministry of Education and Research (01EW1903); consulting fees from Brainsway (Jerusalem, Israel) as a member of the European Scientific Advisory Board and from Sooma (Helsinki, Finland) as a member of the International Scientific Advisory Board; honoraria for workshops from Mag&More (Munich, Germany) and honoraria for lectures from the NeuroCare Group and Brainsway; and has received equipment from Mag&More, the NeuroCare Group, and Brainsway.

References

376

377

378

379

380

381

382

383

384

385

386

387

388

389

- 390 Institute of Health Metrics and Evaluation. Global Health Data Exchange (GHDx).
- 391 2022.http://ghdx.healthdata.org/gbd-results-tool?params=gbd-api-2019-
- 392 permalink/d780dffbe8a381b25e1416884959e88b.
- 393 Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME et al. Bupropion-
- 394 SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression. N Engl J Med 2006;
- 395 **354**: 1231–1242.
- 396 Fried EI, Nesse RM. Depression is not a consistent syndrome: An investigation of unique 397 symptom patterns in the STAR*D study. Journal of Affective Disorders 2015; 172: 96–102.
- 398 Monroe SM, Harkness KL. Major Depression and Its Recurrences: Life Course Matters. Annu 399 Rev Clin Psychol 2022; 18: 329–357.
- 400 Border R, Johnson EC, Evans LM, Smolen A, Berley N, Sullivan PF et al. No Support for 401 Historical Candidate Gene or Candidate Gene-by-Interaction Hypotheses for Major Depression 402 Across Multiple Large Samples. Am J Psychiatry 2019; 176: 376–387.
- 403 Schmaal L, Pozzi E, C. Ho T, van Velzen LS, Veer IM, Opel N et al. ENIGMA MDD: seven 404 years of global neuroimaging studies of major depression through worldwide data sharing. Transl Psychiatry 2020; 10: 172. 405
- 406 Perlman K, Benrimoh D, Israel S, Rollins C, Brown E, Tunteng J-F et al. A systematic meta-407 review of predictors of antidepressant treatment outcome in major depressive disorder. Journal of 408 *Affective Disorders* 2019; **243**: 503–515.

409 Chekroud AM, Zotti RJ, Shehzad Z, Gueorguieva R, Johnson MK, Trivedi MH et al. Cross-trial prediction of treatment outcome in depression: a machine learning approach. The Lancet 410

- 411 Psychiatry 2016; 3: 243–250.
- 412 Koutsouleris N, Wobrock T, Guse B, Langguth B, Landgrebe M, Eichhammer P et al. Predicting
- 413 Response to Repetitive Transcranial Magnetic Stimulation in Patients With Schizophrenia Using
- 414 Structural Magnetic Resonance Imaging: A Multisite Machine Learning Analysis. Schizophrenia
- 415 Bulletin 2018; 44: 1021–1034.
- 416 10 Dong MS, Rokicki J, Dwyer D, Papiol S, Streit F, Rietschel M et al. Multimodal workflows
- 417 optimally predict response to repetitive transcranial magnetic stimulation in patients with
- 418 schizophrenia: a multisite machine learning analysis. Transl Psychiatry 2024; 14: 196.
- 419 11 Nie Z, Vairavan S, Narayan VA, Ye J, Li QS. Predictive modeling of treatment resistant
- 420 depression using data from STAR*D and an independent clinical study. PLoS One 2018; 13:
- 421 e0197268.
- 422 12 Nunez J-J, Nguyen TT, Zhou Y, Cao B, Ng RT, Chen J et al. Replication of machine learning
- 423 methods to predict treatment outcome with antidepressant medications in patients with major
- 424 depressive disorder from STAR*D and CAN-BIND-1. PLoS One 2021; 16: e0253023.
- 425 13 Meehan AJ, Lewis SJ, Fazel S, Fusar-Poli P, Steyerberg EW, Stahl D et al. Clinical prediction
- 426 models in psychiatry: a systematic review of two decades of progress and challenges. Mol
- 427 Psychiatry 2022; 27: 2700–2708.
- 428 14 Browning M, Bilderbeck AC, Dias R, Dourish CT, Kingslake J, Deckert J et al. The clinical
- 429 effectiveness of using a predictive algorithm to guide antidepressant treatment in primary care
- 430 (PReDicT): an open-label, randomised controlled trial. Neuropsychopharmacol 2021; 46: 1307–
- 431 1314.
- 432 15 Brunoni AR, Valiengo L, Baccaro A, Zanão TA, de Oliveira JF, Goulart A et al. The Sertraline vs
- 433 Electrical Current Therapy for Treating Depression Clinical Study: Results From a Factorial,
- 434 Randomized, Controlled Trial. JAMA Psychiatry 2013; 70: 383.
- 435 16 Brunoni AR, Moffa AH, Sampaio-Junior B, Borrione L, Moreno ML, Fernandes RA et al. Trial
- 436 of Electrical Direct-Current Therapy versus Escitalopram for Depression. N Engl J Med 2017;
- 437 **376**: 2523–2533.
- 438 17 Razza LB, Palumbo P, Moffa AH, Carvalho AF, Solmi M, Loo CK et al. A systematic review
- 439 and meta-analysis on the effects of transcranial direct current stimulation in depressive episodes.
- 440 Depress Anxiety 2020; **37**: 594–608.
- 441 18 Burkhardt G, Kumpf U, Crispin A, Goerigk S, Andre E, Plewnia C et al. Transcranial direct
- 442 current stimulation as an additional treatment to selective serotonin reuptake inhibitors in adults
- 443 with major depressive disorder in Germany (DepressionDC): a triple-blind, randomised, sham-
- 444 controlled, multicentre trial. Lancet
- 2023.https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00640-2/fulltext. 445
- 446 19 Borrione L, Cavendish BA, Aparicio LVM, Luethi MS, Goerigk S, Carneiro AM et al. Home-
- 447 Use Transcranial Direct Current Stimulation for the Treatment of a Major Depressive Episode: A
- 448 Randomized Clinical Trial. JAMA Psychiatry 2024. doi:10.1001/jamapsychiatry.2023.4948.
- 449 20 Woodham RD, Selvaraj S, Lajmi N, Hobday H, Sheehan G, Ghazi-Noori A-R et al. Home-based
- 450 transcranial direct current stimulation RCT in major depression. bioRxiv. 2023.
- 451 doi:10.1101/2023.11.27.23299059.

- 452 21 Padberg F, Bulubas L, Mizutani-Tiebel Y, Burkhardt G, Kranz GS, Koutsouleris N et al. The
- 453 intervention, the patient and the illness – Personalizing non-invasive brain stimulation in
- 454 psychiatry. Experimental Neurology 2021; 341: 113713.
- 455 22 Burkhardt G, Goerigk S, Padberg F, Mood Disorders: Predictors of tDCS Response. In: Brunoni
- 456 AR, Nitsche MA, Loo CK (eds). Transcranial Direct Current Stimulation in Neuropsychiatric
- 457 Disorders: Clinical Principles and Management. Springer International Publishing: Cham, 2021,
- 458 pp 481–490.
- 459 23 Kambeitz J, Goerigk S, Gattaz W, Falkai P, Benseñor IM, Lotufo PA et al. Clinical patterns
- 460 differentially predict response to transcranial direct current stimulation (tDCS) and escitalopram
- 461 in major depression: A machine learning analysis of the ELECT-TDCS study. Journal of
- 462 Affective Disorders 2020; 265: 460–467.
- 463 24 Seibt O, Brunoni AR, Huang Y, Bikson M. The Pursuit of DLPFC: Non-neuronavigated Methods
- 464 to Target the Left Dorsolateral Pre-frontal Cortex With Symmetric Bicephalic Transcranial Direct
- 465 Current Stimulation (tDCS). Brain Stimul 2015; 8: 590–602.
- 466 25 Montgomery SA, Åsberg M. A New Depression Scale Designed to be Sensitive to Change. Br J
- Psychiatry 1979; 134: 382-389. 467
- 468 26 Troyanskaya O, Cantor M, Sherlock G, Brown P, Hastie T, Tibshirani R et al. Missing value
- 469 estimation methods for DNA microarrays. *Bioinformatics* 2001; 17: 520–525.
- 470 27 Burkhardt G, Adorjan K, Kambeitz J, Kambeitz-Ilankovic L, Falkai P, Eyer F et al. A machine
- 471 learning approach to risk assessment for alcohol withdrawal syndrome. European
- Neuropsychopharmacology 2020; **35**: 61–70. 472
- 473 28 Koutsouleris N, Dwyer DB, Degenhardt F, Maj C, Urquijo-Castro MF, Sanfelici R et al.
- 474 Multimodal Machine Learning Workflows for Prediction of Psychosis in Patients With Clinical
- 475 High-Risk Syndromes and Recent-Onset Depression. JAMA Psychiatry 2021; 78: 195–209.
- 476 29 Chang C-C, Lin C-J. LIBSVM: A library for support vector machines. ACM Trans Intell Syst
- 477 Technol 2011; 2: 1–27.
- 30 Brodersen KH, Ong CS, Stephan KE, Buhmann JM. The Balanced Accuracy and Its Posterior 478
- 479 Distribution. 2010, pp 3121–3124.
- 31 Huang Y-M, Du S-X. Weighted support vector machine for classification with uneven training 480
- 481 class sizes. 2005, pp 4365-4369 Vol. 7.
- 482 32 Golland P, Fischl B. Permutation tests for classification: towards statistical significance in image-
- 483 based studies. Inf Process Med Imaging 2003; 18: 330–341.
- 484 33 Koutsouleris N, Kambeitz-Ilankovic L, Ruhrmann S, Rosen M, Ruef A, Dwyer DB et al.
- 485 Prediction Models of Functional Outcomes for Individuals in the Clinical High-Risk State for
- 486 Psychosis or With Recent-Onset Depression: A Multimodal, Multisite Machine Learning
- Analysis. JAMA Psychiatry 2018; 75: 1156–1172. 487
- 488 34 Gómez-Verdejo V, Parrado-Hernández E, Tohka J, Alzheimer's Disease Neuroimaging Initiative.
- 489 Sign-Consistency Based Variable Importance for Machine Learning in Brain Imaging.
- 490 Neuroinformatics 2019; 17: 593-609.
- 491 35 R. Team. R: A language and environment for statistical computing. MSOR connections 2014;
- 492 1.https://apps.dtic.mil/sti/citations/AD1039033.

36 Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. arXiv preprint arXiv:14065823 2014.http://arxiv.org/abs/1406.5823. 37 Browning M, Kingslake J, Dourish CT, Goodwin GM, Harmer CJ, Dawson GR. Predicting treatment response to antidepressant medication using early changes in emotional processing. European Neuropsychopharmacology 2019; 29: 66–75. 38 Wagner DT, Tilmans L, Peng K, Niedermeier M, Rohl M, Ryan S et al. Artificial Intelligence in Neuroradiology: A Review of Current Topics and Competition Challenges. *Diagnostics (Basel)* 2023; 13. doi:10.3390/diagnostics13162670. 39 Bzdok D, Meyer-Lindenberg A, Machine Learning for Precision Psychiatry: Opportunities and Challenges. Biol Psychiatry Cogn Neurosci Neuroimaging 2018; 3: 223–230. 40 Chekroud AM, Hawrilenko M, Loho H, Bondar J, Gueorguieva R, Hasan A et al. Illusory generalizability of clinical prediction models. Science 2024; **383**: 164–167. 41 van der Ploeg T, Austin PC, Steyerberg EW. Modern modelling techniques are data hungry: a simulation study for predicting dichotomous endpoints. BMC Med Res Methodol 2014; 14: 137.